Functional analysis of PIK3CA gene mutations in human colorectal cancer

Cancer Research

Volumn 65, Issue 11, 2005, Pages 4562-4567

  Ikenoue, Tsuneo ^a,b   Kanai, Fumihiko ^a,d   Hikiba, Yohko ^b   Obata, Toshiyuki ^c   Tanaka, Yasuo ^a   Imamura, Jun ^a   Ohta, Miki ^a   Jazag, Amarsanaa ^a   Guleng, Bayasi ^a   Tateishi, Keisuke ^a   Asaoka, Yoshinari ^a   Matsumura, Masayuki ^a   Kawabe, Takao ^a   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b INSTITUTE FOR ADULT DISEASES   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOSPECIFIC ANTIBODY; PHOSPHOTRANSFERASE; PROTEIN KINASE B; PROTEIN P110; S6 KINASE;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL ANCHORAGE; CELL STRAIN 3T3; CELL STRUCTURE; COLORECTAL CANCER; COMPARATIVE STUDY; CONTACT INHIBITION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE; PIK3CA GENE; PRIORITY JOURNAL; WILD TYPE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL ADHESION; CELL GROWTH PROCESSES; COLORECTAL NEOPLASMS; ENZYME ACTIVATION; HUMANS; MICE; NIH 3T3 CELLS; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; TUMOR MARKERS, BIOLOGICAL;

EID: 21144457217     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4114     Document Type: Article

References (27)

1. Cantley LC. The phosphoinositide 3-kinase pathway. Science (Wash DC) 2002;296:1655-7.
2. Wymann MP, Zvelebil M, Laffargue M. Phosphoinositide 3-kinase signalling: which way to target? Trends Pharmacol Sci 2003;24:366-76.
3. Walker EH, Perisic O. Ried C. Stephens L, Williams RL. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature (Lond) 1999;402;313-20.
4. Djordjevic S, Driscoll PC. Structural insight into substrate specificity and regulatory mechanisms of phosphoinositide 3-kinases. Trends Biochem Sci 2002;27:426-32.
5. Rodriguez-Viciana P, Warne PH, Dhand R, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature (Lond) 1994;370:527-32.
6. Rodriguez-Viciana P, Warne PH, Khwaja A, et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 1997;89:457-67.
7. Singh B, Reddy PG, Goberdhan A, et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev 2002;16:984-93.
8. Chang HW, Aoki M, Fruman D, et al. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science (Wash DC) 1997;276:1848-50.
9. Klippel A, Escobedo MA, Wachowicz MS. et al. Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol Cell Biol 1998;18:5699-711.
10. Aoki M, Batista O, Bellacosa A, Tsichlis P, Vogt PK. The Akt kinase: molecular determinants of oncogenicity. Proc Natl Acad Sci U S A 1998;95:14950-5.
11. Sakoda H, Gotoh Y, Katagiri H, et al. Differing roles of Akt and serum- and glucocorticoid-regulated kinase in glucose metabolism, DNA synthesis, and oncogenic activity. J Biol Chem 2003; 278:25802-7.
12. Aoki M, Blazek E, Vogt PK. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A 2001;98: 136-41.
13. Vivanco I. Sawyers CL. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
14. Luo J, Manning BD, Cantley LC. Targeting the PI3K Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257-62.
15. Philp AJ, Campbell IG, Leet C, et al. The phosphatidylinositol 3′-kinase p85α gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001;61: 7426-9.
16. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21: 99-102.
17. Samuels Y. Wang Z, Bardelli A. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science (Wash DC) 2004;304:554.
18. Campbell IG, Russell SE, Choong DYH, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004;64:7678-81.
19. Ikenoue T, Hikiba Y, Kanai F, et al. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/ extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor κB pathway and cellular transformation. Cancer Res 2004;64: 3428-35.
20. Ikenoue T, Hikiba Y, Kanai F, et al. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res 2003;63:8132-7.
21. McFall A, Ulku A, Lambert QT, Kusa A, Rogers-Graham K, Der CJ. Oncogenic Ras blocks anoikis by activation of a novel effector pathway independent of phosphatidylinositol 3-kinase. Mol Cell Biol 2001;21:5488-99.
22. Cheng JQ, Altomare DA, Klein MA, et al. Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis. Oncogene 1997;14:2793-801.
23. Rodriguez-Viciana P, Warne PH, Vanhaesebroeck B, Waterfield MD, Downward J. Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J 1996;15:2442-51.
24. Yu J, Zhang Y, McIlroy J, et al. Regulation of the p85/p110 phosphatidylinositol 3′-kinase: stabilization and inhibition of the p110α catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 1998;18:1379-87.
25. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 2005;102:802-7.
26. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
27. Khaleghpour K, Li Y, Banville D, Yu Z, Shen SH. Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma. Carcinogenesis 2004;25:241-8.